13-cis-retinoic acid and interferon α -2a: Effective combination. Therapy for advanced squamous cell carcinoma of the skin

Journal of the National Cancer Institute

Volumn 84, Issue 4, 1992, Pages 235-241

  Lippman, Scott M ^a   Parkinson, David R ^a   Itri, Loretta M ^b   Weber, Randal S ^a   Schantz, Stimson P ^a   Ota, David M ^a   Schusterman, Mark A ^a   Krakoff, Irwin H ^a   Gutterman, Jordan U ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hoffmann La Roche ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ADVANCED CANCER; AGED; CANCER COMBINATION CHEMOTHERAPY; CHEILITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONJUNCTIVITIS; DRUG RESPONSE; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFLUENZA; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DRUG EVALUATION; FEMALE; HUMAN; INTERFERON ALFA-2A; ISOTRETINOIN; MALE; MIDDLE AGE; REMISSION INDUCTION; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0026583597     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.4.235     Document Type: Article

References (50)

1. Stegman SJ: Basal cell carcinoma and squamous cell carcinoma. Recognition and treatment. Med Clin North Am 70:95–107, 1986
2. Patterson JAK, Geronemus RG: Cancers of the skin. In Cancer: Principles and Practice of Oncology, 3rd ed (DeVita VT Jr, Heilman S, Rosenberg, SA, eds). Philadelphia: Lippincott, 1989, pp 1469–1498
3. Stoll H Jr, Schwartz RA: Squamous cell carcinoma. In Dermatology in General Medicine, 3rd ed (Fitzpatrick TB, Eisen AZ, Wolff K. et al, eds). New York: McGraw-Hill, 1987, pp 746–758
4. Levine HL, Ratz JL, Bailin P: Squamous cell carcinoma of the head and neck. Selective management according to site and stage—skin. Otolaryngol Clin North Am 18:499–503. 1983
5. Brady LW, Binnick SA, Fitzpatrick PJ: Skin cancer. In Principles and Practice of Radiation Oncology (Perez CA, Brady RW, eds). Philadelphia: Lippincott, 1987, pp 377–394
6. Chernosky ME: Squamous cell and basal cell carcinomas: Preliminary study of 3,817 primary skin cancers. South Med J 71:802–803,806, 1978
7. Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8:342–346, 1990
8. Sadek H, Azli N, Wendling JL, et al: Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692–1696, 1990
9. Sporn MB, Roberts AB, Roche NS, et al: Mechanism of action of retinoids. J Am Acad Dermatol 15:756–764, 1986
10. Evans RM: The steroid and thyroid hormone receptor super-family. Science 240:889–895, 1988
11. Lotan R, Francis GE, Freeman CS, et al: Differentiation therapy. Cancer Res 50:3453–3464, 1990
12. Langer JA, Pestka S: Interferon receptors. Immunol Today 9:393–400, 1988
13. Pitha PM: Interferons: A new class of tumor suppressor genes? Cancer Cells 2:215–216, 1990
14. Pestka S, Langer JA, Zoon KC, et al: Interferons and their actions. Annu Rev Biochem 56:727–777, 1987
15. Grossberg SE, Taylor JL, Kushnaryov VM: Interferon receptors and their role in interferon action. Experientia 45:508–513, 1989
16. Hemmi H, Breitman TR: Combinations of recombinant human interferons and retinoic acid synergistically induced differentiation of the human promyelocytic leukemia cell line HL-60. Blood 69:501–507, 1987
17. Gallagher RE, Lurie KJ, Leavitt RD, et al: Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon. Leuk Res 11:609–619, 1987
18. Peck R, Bollag W: Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 27:53–57, 1991
19. Marth C, Daxenbichler G, Dapunt O: Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. JNCI 77:1197–1202, 1986
20. Marth C, Kirchebner P, Daxenbichler G: The role of polyamines in interferon and retinoic acid mediated synergistic antiproliferative action. Cancer Lett 44:55–59, 1989
21. Higuchi T, Hannigan GE, Malkin D, et al: Enhancement by retinoic acid and dibutyryl cyclic adenosine 3′:5′-monophosphate of the differentiation and gene expression of human neuroblastoma cells induced by interferon. Cancer Res 51:3958–3964, 1991
22. Frey JR, Peck R, Bollag W: Antiproliferative activity of retinoids, interferon-α and their combination in five human transformed cell lines. Cancer Lett 57: 223–227, 1991
23. Bollag W: Vitamin A and retinoids: From nutrition to pharmacotherapy in dermatology and oncology. Lancet 1:860–863, 1983
24. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 71:391–405 (part I)
25. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 493–515 (part II), 1987
26. Goldstein D, Laszlo J: The role of interferon in cancer therapy: A current perspective. CA 38:258–277, 1988
27. Wolf G, Lippman SM, Laramore G, et al: Head and neck cancer. In Cancer Medicine, 3rd ed (Holland JF, Frei E, Bast RC Jr, et al, eds). Philadelphia: Lea & Febiger. In press
28. Kraemer KH, DiGiovanna JJ, Moshell AN, et al: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633–1637, 1988
29. Lippman SM, Meyskens FL Jr: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107:499–502, 1987
30. Lippman SM, Meyskens FL Jr: Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther 40:107–122, 1989
31. Taguchi T: Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57:1705–1708, 1986
32. Gutterman JU, Fine S, Quesada J, et al: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96:549–556, 1982
33. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159, 1990
34. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346–353, 1961
35. Fleiss JL: Statistical Methods for Rates and Proportions, 2nd ed. New York: John Wiley & Sons, 1981
36. Holoye PY, Byers RM, Gard DA, et al: Combination chemotherapy of head and neck cancer. Cancer 42:1661–1669, 1978
37. Hong WK, Endicott J, Itri LM, et al: 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505, 1986
38. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801, 1990
39. Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385–1393, 1991
40. Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18, 1984
41. Talpaz M, Kantarjian H, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114:532–538, 1991
42. Lippman SM, Lee JS, Lotan R, et al: Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 82:555–560, 1990
43. Ingber D, Folkman J: Inhibition of an-giogenesis through modulation of collagen metabolism. Lab Invest 59:44–51, 1988
44. Folkman J: Successful treatment of an angiogenic disease [editorial]. N Engl J Med 320:1211–1212,1989
45. Zheng ZS, Goldsmith LA: Modulation of epidermal growth factor receptors by retinoic acid in ME180 cells. Cancer Res 50:1201–1205, 1990
46. Sporn MB, Roberts AB: TGF-β: Problems and prospects. Cell Regul 1:875–882, 1990
47. Cope FO, Wille JJ: Retinoid receptor antisense DNAs inhibit alkaline phosphatase induction and clonogenicity in malignant keratinocytes. Proc Natl Acad Sci USA 86:5590–5594, 1989
48. Tyring SK: Antitumor actions of interferons. Direct, indirect, and synergy with other treatment modalities. Int J Dermatol 26:549–556, 1987
49. Opdenakker G, Cabeza-Arvelaiz Y, Van Damme J: Interaction of interferon with other cytokines. Experientia 45:513–520, 1989
50. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473–3486, 1990